Do Not Attempt Resuscitation (DNAR) status in people with suspected COVID-19 : secondary analysis of the PRIEST observational cohort study by Sutton, L. et al.
This is a repository copy of Do Not Attempt Resuscitation (DNAR) status in people with 
suspected COVID-19 : secondary analysis of the PRIEST observational cohort study.




Sutton, L., Goodacre, S. orcid.org/0000-0003-0803-8444, Thomas, B. et al. (1 more 
author) (Submitted: 2021) Do Not Attempt Resuscitation (DNAR) status in people with 






This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Do Not Attempt Resuscitation (DNAR) status in people with 
suspected COVID-19: Secondary analysis of the PRIEST 
observational cohort study 
 
Laura Sutton, Statistician/Research Associate, University of Sheffield, UK, l.j.sutton@sheffield.ac.uk 
Steve Goodacre, Professor of Emergency Medicine, University of Sheffield, UK, 
s.goodacre@sheffield.ac.uk 
Ben Thomas, Study Manager, University of Sheffield, UK, b.d.thomas@sheffield.ac.uk 
Sarah Connelly, Research Assistant, University of Sheffield, UK, s.l.connelly@sheffield.ac.uk 
 
Corresponding author: 
Steve Goodacre, School of Health and Related Research (ScHARR), University of Sheffield, Regent 
Court, Regent Street, Sheffield, S10 1UL 
s.goodacre@sheffield.ac.uk  
ORCID ID: 0000-0003-0803-8444 
 
Word count: 2378  
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.23.21249978doi: medRxiv preprint 




Cardiac arrest is common in people admitted with suspected COVID-19 and has a poor prognosis. Do 
Not Attempt Resuscitation (DNAR) orders can reduce the risk of futile resuscitation attempts but 
have raised ethical concerns. 
 
Objectives 
We aimed to describe the characteristics and outcomes of adults admitted to hospital with 




We undertook a secondary analysis of 13977 adults admitted to hospital with suspected COVID-19 
and included in the Pandemic Respiratory Infection Emergency System Triage (PRIEST) study. We 
recorded presenting characteristics and outcomes (death or organ support) up to 30 days. We 
categorised patients as early DNAR (occurring before or on the day of admission) or late/no DNAR 
(no DNAR or occurring after the day of admission). We undertook descriptive analysis comparing 
these groups and multivariable analysis to identify independent predictors of early DNAR. 
 
Results 
We excluded 1249 with missing DNAR data, and identified 3929/12748 (31%) with an early DNAR 
decision. They had higher mortality (40.7% v 13.1%) and lower use of any organ support (11.6% v 
15.7%), but received a range of organ support interventions, with some being used at rates 
comparable to those with late or no DNAR (e.g. non-invasive ventilation 4.4% v 3.5%). On 
multivariable analysis, older age (p<0.001), active malignancy (p<0.001), chronic lung disease 
(p<0.001), limited performance status (p<0.001), and abnormal physiological variables were 
associated with increased recording of early DNAR. Asian ethnicity was associated with reduced 
recording of early DNAR (p=0.001). 
 
Conclusions 
Early DNAR decisions were associated with recognised predictors of adverse outcome, and were 
inversely associated with Asian ethnicity. Most people with an early DNAR decision survived to 30 
days and many received potentially life-saving interventions. 
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Introduction 
In-hospital cardiac arrest is relatively common in patients with COVID-19 and often results in poor 
outcome. A multicentre cohort study from the United States [1] reported that 701/5019 (14.0%) 
critically ill patients with COVID-19 had in-hospital cardiac arrest, with 400/701 (57.1%) receiving 
CPR, and only 7% of these surviving to hospital discharge with normal or mildly impaired 
neurological status. Management of cardiac arrest in COVID-19 is further complicated by concerns 
about infection risk associated with aerosol-generating procedures and consequent risks to staff. [2] 
 
These concerns have raised awareness about the need to consider do not attempt resuscitation 
(DNAR) decisions when patients are admitted to hospital with suspected COVID-19. An appropriately 
implemented DNAR decision can ensure that the patient’s wishes and best interests are addressed, 
while avoiding futile medical intervention.[3] However, concerns have been raised about 
inappropriate use of DNAR orders during the pandemic, [4] leading to the Care Quality Commission 
being asked to review their use in the United Kingdom (UK). [5] 
 
Previous studies have estimated the prevalence of DNAR orders in patients admitted to hospital with 
community-acquired pneumonia [6-10] and sepsis,[11-14] and have attempted to identify factors 
associated with DNAR use, but we currently know very little about how DNAR orders have been used 
in people admitted with suspected COVID-19. The Pandemic Respiratory Infection Emergency 
System Triage (PRIEST) study was established to develop and evaluate triage tools for people 
presenting to hospital emergency departments with suspected COVID-19.[15] DNAR status was 
recorded to facilitate evaluation of triage tools in pre-specified subgroups. We present a post hoc 
secondary analysis of patients admitted with suspected COVID-19 that aims to describe their 
characteristics and outcomes according to their DNAR status and identify factors associated with 
recording of a DNAR decision. 
 
Methods 
PRIEST was an observational cohort study of patients attending an emergency department (ED) in 
the UK with suspected COVID-19 infection during the first wave of the pandemic. We included 
patients if the assessing clinician recorded that the patient had suspected COVID-19 in the ED 
records or completed a standardised assessment form for suspected COVID-19 patients. The clinical 
diagnostic criteria for COVID-19 during the study were of fever (≥ 37.8°C) and at least one of the 
following respiratory symptoms, which must be of acute onset: persistent cough (with or without 
sputum), hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing, 
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sneezing. We did not seek consent to collect data but information about the study was provided in 
the ED and patients could withdraw their data at their request. Patients with multiple presentations 
to hospital were only included once, using data from the first presentation identified by research 
staff. 
 
We only included patients who were admitted to hospital after ED assessment because DNAR 
planning was considered unlikely to be routinely undertaken for discharged patients and would be 
limited to a minority of highly selected cases. We also only included adults (age ≥ 16 years) because 
previous analysis [15] showed that children with suspected COVID-19 had very low rates of 
confirmed COVID-19 or adverse outcome. 
 
Baseline characteristics at presentation to the ED were recorded prospectively, using a standardised 
assessment form that doubled as a clinical record (Appendix 1: Standardised Data Collection Form), 
or retrospectively, through research staff extracting data onto the standardised form using the 
clinical records. Research staff collected follow-up data onto a standardised follow-up form 
(Appendix 2: Follow-up Form) using clinical records up to 30 days after presentation. This included 
recording whether a DNAR decision made at any time between initial presentation and follow-up, 
and if so, the date of the decision. 
 
Patients who died or required respiratory, cardiovascular, or renal support were classified as having 
an adverse outcome. Patients who survived to 30 days without requiring respiratory, cardiovascular 
or renal support were classified as having no adverse outcome. Respiratory support was defined as 
any intervention to protect the patient’s airway or assist their ventilation, including non-invasive 
ventilation, or acute administration of continuous positive airway pressure. It did not include 
supplemental oxygen alone or nebulised bronchodilators. Cardiovascular support was defined as any 
intervention to maintain organ perfusion, such as inotropic drugs, or invasively monitor 
cardiovascular status, such as central venous pressure or pulmonary artery pressure monitoring, or 
arterial blood pressure monitoring. It did not include peripheral intravenous cannulation, or fluid 
administration. Renal support was defined as any intervention to assist renal function, such as 
haemofiltration, haemodialysis, or peritoneal dialysis. It did not include intravenous fluid 
administration. 
 
We compared the characteristics and outcomes of those with a DNAR decision recorded on or 
before the day of ED assessment (early DNAR) to those with no DNAR recorded or a DNAR decision 
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recorded at a later date (late/no DNAR). We categorised patients in this way on the assumption that 
patients with a late DNAR decision were likely to be systematically different from those with an early 
decision, with implementation of a late DNAR decision reflecting the response to intervention. Our 
categorisation was therefore based on a theoretical framework in which patient characteristics at 
admission could determine whether a DNAR decision was recorded at hospital admission, and 
recording of a DNAR decision at admission could then determine subsequent use of interventions. 
 
We calculated a National Early Warning Score (2nd version, NEWS2) for adults, [16] to provide an 
overall assessment of acute illness severity on a score from zero to 20, based on respiratory rate, 
oxygen saturation, systolic blood pressure, heart rate, level of consciousness and temperature. We 
calculated a PRIEST COVID-19 clinical severity score, to provide an overall prediction of the risk of 
adverse outcome on a score from zero to 29, based on NEWS2, age, sex and performance status [17]. 
 
We also undertook multivariable logistic regression modelling to identify independent predictors of 
DNAR status. Variables were selected on the basis of clinical interest. Collinearity was observed 
between Glasgow Coma Scale (GCS) scores and consciousness, recorded as alert, responsive to 
verbal stimuli, responsive to pain or unconscious (AVPU). Missing AVPU data were imputed using 
GCS as follows, and GCS dropped from the list of predictors: GCS 15 = Alert, GCS 9-14 = Verbal, GCS 
7-8 = Pain, and GCS 3-6 = Unresponsive. Continuous physiological predictors were categorised in 
accordance with NEWS2 risk categories [16] where the reference category denotes normal range 
and increasing category levels indicate increasing deviation from the norm. Data were analysed 
using SAS v9.4. 
 
Ethical approval 
The North West - Haydock Research Ethics Committee (REC) gave a favourable opinion on the 
PAINTED study on 25 June 2012 (reference 12/NW/0303) and on the updated PRIEST study on 23rd 
March 2020. The Confidentiality Advisory Group of the Health Research Authority granted approval 
to collect data without patient consent in line with Section 251 of the National Health Service Act 




The PRIEST study recruited 22484 patients from 70 EDs across 53 sites between 26 March 2020 and 
28 May 2020, including 13997 adults admitted following ED assessment. Of these, 1249 had 
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unknown DNAR status or timing, and were excluded from the analysis. The remaining 12748 were 
grouped into those with DNAR decisions made on or before the day of initial ED assessment (N=3929, 
31%) and those with no DNAR or DNAR decisions made at a later date (N=8819). 
 
Table 1 shows presenting characteristics for both groups. Patients with a DNAR decision recorded on 
or before their day of attendance tended to be older and have a higher prevalence of comorbidities, 
limited activity or self-care. They also tended to have a slightly higher respiratory rate, lower oxygen 
saturation, and lower Glasgow Coma Scale (GCS), and were less likely to be alert.  
 
Table 1. Presenting characteristics for admitted adults with DNAR decisions in place 
by the end of ED assessment (N=3929) and adults with no DNAR or DNAR decision 
made later (N=8819) 
Characteristic Statistic/level Early DNAR No/late DNAR 
Age (years) N 3929 8819 
 Mean (SD) 79.4 (10.9) 63.9 (17.6) 
 Median (IQR) 81 (73,87) 65 (52,78) 
Sex Missing 42 78 
 Male 2027 (52.1%) 4704 (53.8%) 
 Female 1860 (47.9%) 4037 (46.2%) 
Ethnicity Missing/prefer not to say 601 1746 
 UK/Irish/other white 3102 (93.2%) 6027 (85.2%) 
 Asian 83 (2.5%) 468 (6.6%) 
 Black/African/Caribbean 75 (2.3%) 289 (4.1%) 
 Mixed/multiple ethnic groups 27 (0.8%) 102 (1.4%) 
 Other 41 (1.2%) 187 (2.6%) 
Presenting features Cough 2117 (53.9%) 5514 (62.5%) 
 Shortness of breath 2955 (75.2%) 6678 (75.7%) 
 Fever 1777 (45.2%) 4688 (53.2%) 
Comorbidities No Chronic disease 323 (8.2%) 2012 (22.8%) 
 Heart Disease 1620 (41.2%) 2036 (23.1%) 
 Renal impairment 739 (18.8%) 843 (9.6%) 
 Steroid therapy 160 (4.1%) 258 (2.9%) 
 Asthma 450 (11.5%) 1446 (16.4%) 
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Characteristic Statistic/level Early DNAR No/late DNAR 
 Diabetes 1123 (28.6%) 2034 (23.1%) 
 Active malignancy 370 (9.4%) 508 (5.8%) 
 Immunosuppression 126 (3.2%) 326 (3.7%) 
 Other chronic lung disease 1219 (31%) 1685 (19.1%) 
 Hypertension 1721 (43.8%) 3039 (34.5%) 
Symptom duration (days) N 3396 7986 
 Mean (SD) 5.7 (6.8) 7.5 (8.4) 
 Median (IQR) 3 (1,7) 5 (2,10) 
Heart rate (beats/min) N 3867 8664 
 Mean (SD) 95.5 (23) 97.4 (22) 
 Median (IQR) 93 (80,109) 96 (82,111) 
Respiratory rate (breaths/min) N 3867 8625 
 Mean (SD) 25.5 (7.5) 23.9 (6.9) 
 Median (IQR) 24 (20,29) 22 (19,28) 
Systolic BP (mmHg) N 3834 8629 
 Mean (SD) 131.8 (27.8) 134.1 (25.6) 
 Median (IQR) 130 (112,149) 132 (117,149) 
Diastolic BP (mmHg) N 3813 8587 
 Mean (SD) 73.5 (17.1) 77.4 (16.3) 
 Median (IQR) 72 (62,84) 77 (67,87) 
Temperature (°C)  N 3803 8576 
 Mean (SD) 37.1 (1.2) 37.3 (1.2) 
 Median (IQR) 37 (36.4,37.9) 37.2 (36.5,38.1) 
Oxygen saturation (%) N 3893 8741 
 Mean (SD) 92.6 (8) 94.1 (6.8) 
 Median (IQR) 95 (91,97) 96 (93,98) 
Glasgow Coma Scale N 2985 6643 
 Mean (SD) 13.9 (2.1) 14.7 (1.3) 
 Median (IQR) 15 (14,15) 15 (15,15) 
AVPU Missing 610 1009 
 Alert 2877 (86.7%) 7486 (95.9%) 
 Verbal 291 (8.8%) 229 (2.9%) 
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Characteristic Statistic/level Early DNAR No/late DNAR 
 Pain 97 (2.9%) 50 (0.6%) 
 Unresponsive 54 (1.6%) 45 (0.6%) 
Performance status Missing 222 455 
 Unrestricted normal activity 453 (12.2%) 4341 (51.9%) 
 
Limited strenuous activity, can do 
light activity 448 (12.1%) 1160 (13.9%) 
 Limited activity, can self care 923 (24.9%) 1351 (16.2%) 
 Limited self care 1153 (31.1%) 993 (11.9%) 
 Bed/chair bound, no self care 730 (19.7%) 519 (6.2%) 
NEWS2 score N 3911 8723 
 Mean (SD) 6.4 (3.3) 5.1 (3.1) 
 Median (IQR) 6 (4,9) 5 (3,7) 
PRIEST score N 3870 8645 
 Mean (SD) 12.5 (3.9) 8.9 (4.1) 
 Median (IQR) 12 (10,15) 9 (6,12) 
 
Figures 1 compares the NEWS2 scores for the two groups and shows that those with early DNAR 
decisions tended to be more acutely unwell (median score 6 versus 5). Figure 2 compares the PRIEST 
COVID-19 clinical severity scores for the two groups and shows that those with early DNAR decisions 
were at a higher risk of adverse outcome (median score 12 versus 9, respectively indicating 38% 
versus 26% expected risk of a 30-day adverse outcome) [17]. 
 
Table 2 gives location of admission, pathogen confirmation and adverse outcome data for the two 
groups. Patients with an early DNAR decision had a higher mortality rate but most (59.4%) survived 
to 30 days. They also had lower use of critical care and organ support, but a significant proportion 
(11.6%) received organ support. Table 2 shows the highest level of organ support received, 
according to a predefined hierarchy (corresponding to the order presented in the table). Patients 
with early DNAR decisions received a wide range of interventions, some at comparable rates to 
those with no or a late DNAR decision (e.g. non-invasive ventilation and high flow nasal oxygen). 
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Table 2. Outcome data for admitted adults with DNAR decisions in place by the end 
of ED assessment (N=3929) and adults with no DNAR or DNAR decision made later 
(N=8819) 
Outcome Level Early DNAR No/late DNAR 
Location of first admission Missing 98 194 
 Ward 3717 (97%) 7802 (90.5%) 
 ITU 57 (1.5%) 667 (7.7%) 
 HDU 57 (1.5%) 156 (1.8%) 
Respiratory pathogen COVID-19 1791 (45.6%) 3367 (38.2%) 
 Influenza (pandemic or seasonal) 6 (0.2%) 14 (0.2%) 
 Other 235 (6%) 701 (7.9%) 
 None identified 1897 (48.3%) 4737 (53.7%) 
Mortality status Missing 0 0 
 Alive 2328 (59.3%) 7668 (86.9%) 
 Dead 1601 (40.7%) 1151 (13.1%) 
      Death with organ support 251 (15.7%) 373 (32.4%) 
      Death without organ support 1350 (84.3%) 778 (67.6%) 
Organ support Respiratory 423 (10.8%) 1313 (14.9%) 
      Mechanical ventilation 51 (1.3%) 509 (5.8%) 
      Non-invasive ventilation 173 (4.4%) 292 (3.3%) 
      Continuous positive airway  pressure 125 (3.2%) 386 (4.4%) 
      High-flow nasal oxygen 74 (1.9%) 126 (1.4%) 
 Cardiovascular 47 (1.2%) 426 (4.8%) 
      Extracorporeal membrane oxygenation 0 (0%) 13 (0.1%) 
      Inotropic/vasopressor drugs 29 (0.7%) 283 (3.2%) 
      Central venous pressure measurement 2 (0.1%) 25 (0.3%) 
      Intra-arterial BP measurement 16 (0.4%) 105 (1.2%) 
 Renal 29 (0.7%) 172 (2%) 
      Haemofiltration 7 (0.2%) 93 (1.1%) 
      Haemodialysis 22 (0.6%) 75 (0.9%) 
      Peritoneal dialysis 0 (0%) 4 (0%) 
 Any 455 (11.6%) 1386 (15.7%) 
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Table 3 shows the results of the multivariable logistic regression model. Older age, active malignancy, 
chronic lung disease, limited performance status, abnormal heart rate, abnormal respiratory rate, 
lower oxygen saturation, and lower alertness were all associated with increased use of early DNAR. 
Asian ethnicity was associated with a lower use of early DNAR.  
 
Table 3. Multivariable analysis of predictors of early DNAR use 
Effect Odds ratio 95% CI p-value 
Age 1.054 (1.049, 1.060) <0.001 
Male sex 1.010 (0.905, 1.128) 0.859 
Ethnicity (ref=UK/Irish/other white) 
     Asian 0.571 (0.416, 0.783) 0.001 
     Black/African/Caribbean 0.730 (0.524, 1.017) 0.063 
     Mixed/multiple ethnic groups 0.993 (0.568, 1.737) 0.982 
     Other 0.647 (0.410, 1.020) 0.061 
Shortness of breath 1.150 (1.005, 1.316) 0.042 
Cough 1.012 (0.903, 1.133) 0.841 
Fever 0.954 (0.851, 1.069) 0.415 
No chronic disease 0.753 (0.609, 0.931) 0.009 
Heart disease 1.182 (1.048, 1.333) 0.006 
Renal impairment 1.241 (1.067, 1.445) 0.005 
Steroid therapy 1.268 (0.971, 1.657) 0.082 
Asthma 0.900 (0.765, 1.060) 0.209 
Diabetes 1.120 (0.987, 1.271) 0.080 
Active malignancy 1.604 (1.319, 1.951) <0.001 
Immunosuppression 1.117 (0.835, 1.494) 0.455 
Other chronic lung disease 1.456 (1.280, 1.656) <0.001 
Hypertension 0.883 (0.786, 0.993) 0.038 
Symptom duration (days) 0.993 (0.986, 1.001) 0.076 
Pulse rate (beats/min; ref=51-90) 
     41-50 or 91-110 1.121 (0.987, 1.274) 0.079 
     111-130 1.095 (0.929, 1.290) 0.280 
     ≤40 or ≥131 1.030 (0.816, 1.300) 0.802 
Respiratory rate (breaths/min; ref=12-20) 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.23.21249978doi: medRxiv preprint 
Effect Odds ratio 95% CI p-value 
     9-11 0.772 (0.115, 5.173) 0.790 
     21-24 1.175 (1.019, 1.355) 0.027 
     ≤8 or ≥25 1.361 (1.187, 1.560) <0.001 
Systolic BP (mmHg; ref=111-219) 
     101-110 1.164 (0.968, 1.400) 0.107 
     91-100 1.347 (1.066, 1.703) 0.013 
     ≤90 or ≥220 1.177 (0.891, 1.555) 0.251 
Temperature (°C; ref=36.1-38.0) 
     35.1-36.0 or 38.1-39.0 0.916 (0.807, 1.039) 0.173 
     ≥39.1 0.885 (0.693, 1.131) 0.330 
     ≤35.0 1.085 (0.764, 1.540) 0.650 
Oxygen saturation (%; ref=≥96) 
     94-95 1.041 (0.898, 1.206) 0.595 
     92-93 1.127 (0.938, 1.354) 0.203 
     ≤91 1.329 (1.153, 1.532) <0.001 
AVPU (ref=Alert) 
     Verbal 1.905 (1.563, 2.323) <0.001 
     Pain 2.651 (1.644, 4.272) <0.001 
     Unresponsive 2.620 (1.429, 4.803) 0.002 
Performance status (ref=Unrestricted normal activity)  
     Limited strenuous activity, can do light activity 1.885 (1.565, 2.269) <0.001 
     Limited activity, can self care 2.629 (2.222, 3.110) <0.001 
     Limited self care 4.100 (3.448, 4.876) <0.001 
     Bed/chair bound, no self care 5.437 (4.438, 6.660) <0.001 
 
Discussion 
We found that 31% of adults admitted to hospital with suspected COVID-19 during the first phase of 
the pandemic had a DNAR decision recorded on or before their day of attendance, after excluding 
those who could not be classified. Most patients (59.4%) with an early DNAR decision survived to 30 
days and 11.6% received some form of organ support. These findings show that potentially life-
saving treatments were provided to a significant proportion of people, potentially addressing 
concerns that DNAR decisions may be conflated with ‘do not provide active treatment’.[18] The use 
of invasive intervention, particularly mechanical ventilation, in people with a DNAR decision was an 
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unexpected finding. Contact with participating site investigators suggested that this could be 
explained by use of the ReSPECT process in discussions about resuscitation, in which the patient is 
encouraged to explicitly indicate which treatments they want in a future situation where they are 
unable to make or express choices.[19] The ReSPECT process therefore allows patients to consent to 
mechanical ventilation but decline cardiopulmonary resuscitation if it is subsequently required. 
 
Older age, active malignancy, chronic lung disease (excluding asthma), and lower performance status 
were associated with increased use of early DNAR, whereas Asian ethnicity was associated with 
decreased use. Patients with early DNAR status tended to be more acutely ill, with higher NEWS2 
scores. Abnormal respiratory rate, lower oxygen saturation, and lower alertness were associated 
with increased use of early DNAR. 
 
Our findings suggest a higher rate of DNAR use (31%) than identified in previous studies of similar 
conditions. Studies of patients admitted with community-acquired pneumonia reported rates of 
DNAR use ranging from 13% to 29%, [6-10] while studies in severe sepsis or septic shock reported 
rates ranging from 9% to 20%. [11-14] DNAR decisions in these studies were associated with older 
age, but conflicting findings were reported around the use of invasive procedures. Sakari et al [11] 
and Bradford et al [12] reported that DNAR orders were associated with lower rates of invasive 
procedures, while Powell et al [13] reported no difference, and Huang et al [14] reported a higher 
rate of arterial or central venous cannulation in those with a DNAR order. 
 
We found an association between Asian ethnicity and decreased use of early DNAR status compared 
to White ethnicity. The odds ratio for Black/African/Caribbean ethnicity also suggested decreased 
use but was not significant. Previous studies from the United States have shown less use of DNAR 
decisions among African-American, Asian, and Hispanic patients, [20,21,22] and Black patients tend 
to receive more life-prolonging treatment at end of life care.[23] A systematic review of end of life 
decisions for people from ethnic minority groups suggested that Hispanic and African American 
people had advance care plans documented less often, citing religious coping and spirituality as 
factors.[24] A scoping review of culturally- and spiritually-sensitive end-of-life care highlighted a 
multitude of factors influencing end-of-life care and subsequent experiences by culturally- and 
spiritually-diverse groups.[25] Further research of DNAR decisions in relation to ethnicity is clearly 
required. 
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Studies of DNAR use in COVID-19 are currently limited. Alhatem et al [26] analysed 1270 patients 
admitted across two hospitals with COVID-19, of whom 750/1270 (59%) had a DNAR order at 
admission, and 570/750 (76%) of these died. Age over 60, male sex, and comorbidities were 
associated with DNAR at admission. Coleman et al [27] examined records of DNAR decisions at a 
single centre from 2017 to 2020 and showed an increased rate of DNAR use during pandemic, with 
patients tending to be younger and have fewer comorbidities. It is unclear whether these findings 
reflect an increased overall need for DNAR decisions during the pandemic or increased willingness to 
use DNAR decisions in COVID-19. Our findings suggest that a relatively high rate of DNAR use in 
suspected COVID-19 may contribute to an increased rate of DNAR use during the pandemic.  
 
This study was based on a large representative sample of adults admitted with suspected COVID-19, 
but has a number of limitations. DNAR decisions were recorded to facilitate subgroup analyses 
addressing the primary purpose of the study rather than addressing the aims of this secondary 
analysis. We were unable to include 1249/13997 (9%) cases because data were missing or uncertain 
regarding the use or timing for DNAR. Our categorisation on the basis of timing of DNAR decision 
and assumption that later DNAR decisions are qualitatively different to early decisions could be 
challenged. We did not collect any detailed data to allow us to explore the reasons behind DNAR 
decisions, so we are unable to offer explanations for the associations identified in our analysis. Our 
suggestion that the ReSPECT process could explain the use of invasive interventions in people with a 
DNAR decision is based on informal contacts and requires further research. The use of the ReSPECT 
process could also undermine our rationale for categorising DNAR decisions as early versus late or 
no decision, and suggests a complex relationship between DNAR decisions and subsequent 
interventions. 
 
In conclusion, we found that many patients with an early DNAR decision went on to receive life-
saving interventions and most survived to 30 days. Early DNAR decisions were associated with older 
age, lower performance status, active malignancy, chronic lung disease and severe illness, as 
indicated by physiological parameters. We found some evidence of an association between ethnicity 
and DNAR status that requires further research. 
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